US Bancorp’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$26.3M Sell
138,620
-453
-0.3% -$85.2K 0.03% 281
2026
Q1
$27.4M Buy
139,073
+9,521
+7% +$1.84M 0.03% 266
2025
Q4
$23.8M Buy
129,552
+8,461
+7% +$1.48M 0.03% 298
2025
Q3
$18.6M Buy
121,091
+7,533
+7% +$1.14M 0.02% 336
2025
Q2
$15.9M Sell
113,558
-4,823
-4% -$676K 0.02% 354
2025
Q1
$17.4M Sell
118,381
-1,236
-1% -$179K 0.02% 337
2024
Q4
$15.7M Buy
119,617
+3,407
+3% +$477K 0.02% 357
2024
Q3
$18.1M Buy
116,210
+7,483
+7% +$1.21M 0.02% 343
2024
Q2
$17M Buy
108,727
+11,797
+12% +$1.78M 0.02% 337
2024
Q1
$13.1M Buy
96,930
+3,615
+4% +$479K 0.02% 374
2023
Q4
$12.6M Buy
93,315
+15,626
+20% +$2.03M 0.02% 377
2023
Q3
$10.5M Buy
77,689
+7,162
+10% +$978K 0.02% 385
2023
Q2
$10.1M Sell
70,527
-205
-0.3% -$30.2K 0.02% 405
2023
Q1
$9.82M Buy
70,732
+14,353
+25% +$1.93M 0.02% 409
2022
Q4
$7.65M Sell
56,379
-4,316
-7% -$541K 0.01% 460
2022
Q3
$6.66M Sell
60,695
-3,340
-5% -$424K 0.01% 456
2022
Q2
$8.46M Buy
64,035
+5,668
+10% +$744K 0.02% 407
2022
Q1
$7.75M Buy
58,367
+7,935
+16% +$952K 0.01% 473
2021
Q4
$5.88M Sell
50,432
-447
-0.9% -$52.6K 0.01% 545
2021
Q3
$6.11M Buy
50,879
+13,722
+37% +$1.6M 0.01% 525
2021
Q2
$4.45M Buy
37,157
+1,637
+5% +$180K 0.01% 596
2021
Q1
$3.53M Sell
35,520
-2,882
-8% -$290K 0.01% 645
2020
Q4
$3.84M Buy
38,402
+1,920
+5% +$203K 0.01% 595
2020
Q3
$4M Sell
36,482
-6,434
-15% -$716K 0.01% 548
2020
Q2
$4.54M Sell
42,916
-686
-2% -$70.8K 0.01% 506
2020
Q1
$3.89M Buy
43,602
+215
+0.5% +$20.2K 0.01% 488
2019
Q4
$4.33M Sell
43,387
-269
-0.6% -$25.3K 0.01% 552
2019
Q3
$3.89M Buy
43,656
+15,911
+57% +$1.38M 0.01% 567
2019
Q2
$2.29M Buy
27,745
+1,913
+7% +$150K 0.01% 730
2019
Q1
$2.09M Sell
25,832
-7,183
-22% -$566K 0.01% 748
2018
Q4
$2.51M Buy
33,015
+778
+2% +$60.8K 0.01% 655
2018
Q3
$2.55M Sell
32,237
-8
-0% -$605 0.01% 718
2018
Q2
$2.26M Sell
32,245
-2,861
-8% -$206K 0.01% 756
2018
Q1
$2.46M Buy
35,106
+2,825
+9% +$196K 0.01% 714
2017
Q4
$2.24M Buy
32,281
+3,227
+11% +$218K 0.01% 753
2017
Q3
$1.97M Buy
29,054
+1,914
+7% +$121K 0.01% 793
2017
Q2
$1.85M Sell
27,140
-4,145
-13% -$271K 0.01% 796
2017
Q1
$1.95M Sell
31,285
-18,645
-37% -$1.09M 0.01% 787
2016
Q4
$2.73M Sell
49,930
-8,533
-15% -$485K 0.01% 634
2016
Q3
$3.84M Sell
58,463
-12,101
-17% -$791K 0.01% 525
2016
Q2
$4.26M Buy
70,564
+15,389
+28% +$894K 0.02% 478
2016
Q1
$3.11M Sell
55,175
-8,209
-13% -$493K 0.01% 569
2015
Q4
$4.3M Buy
63,384
+4,819
+8% +$316K 0.02% 477
2015
Q3
$3.73M Buy
58,565
+8,978
+18% +$591K 0.02% 509
2015
Q2
$3.16M Buy
49,587
+9,748
+24% +$667K 0.01% 586
2015
Q1
$2.73M Sell
39,839
-18,672
-32% -$1.3M 0.01% 623
2014
Q4
$4.12M Sell
58,511
-12,155
-17% -$870K 0.02% 485
2014
Q3
$5.05M Sell
70,666
-19,367
-22% -$1.42M 0.02% 429
2014
Q2
$6.69M Sell
90,033
-50,004
-36% -$3.61M 0.03% 390
2014
Q1
$9.09M Buy
140,037
+22,506
+19% +$1.45M 0.04% 325
2013
Q4
$6.98M Buy
117,531
+8,024
+7% +$436K 0.03% 356
2013
Q3
$5.69M Buy
109,507
+10,050
+10% +$505K 0.03% 381
2013
Q2
$4.71M Buy
+99,457
New +$5.06M 0.02% 401

Other funds holding AZN

US Bancorp's AZN Position: Q2 2026 in Review

US Bancorp reduced its AstraZeneca (AZN) stake by 0.33% in Q2 2026, selling an estimated $85.2K and leaving 138,620 shares worth $26.3M. The position accounts for 0.03% of the portfolio, ranked #281.

US Bancorp first reported a position in AZN in Q2 2013 and has held it in 53 quarters since. The position peaked at $27.4M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • US Bancorp held 138,620 shares of AstraZeneca worth $26.3M as of Q2 2026.
  • US Bancorp sold 453 AstraZeneca shares in Q2 2026, an estimated $85.2K.
  • AstraZeneca made up 0.03% of US Bancorp's portfolio in Q2 2026, its #281 holding.
  • US Bancorp first reported a position in AstraZeneca in Q2 2013 and has held it in 53 quarters since.
  • US Bancorp's AstraZeneca position peaked at $27.4M in Q1 2026.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.